With Sangamo releasing less than stellar results, gene therapy companies are feeling the effect. More pressure is now being added to gene therapy companies to demonstrate, IN CLINICAL TRIALS, that their approach can be effective.
This is one main reason why my sights are set on OPMD clinical trial results, and not necessarily “additional programs”.